ANTINEOPLASTIC AGENTS. SYNTHESIS OF SOME 1-SUBSTITUTED 5-FLUOROURACIL DERIVATIVES

1975 ◽  
Vol 4 (2) ◽  
pp. 129-130 ◽  
Author(s):  
Masao Tada
Keyword(s):  
Antineoplastic Agents

Design of the functional requirements of a smartphone app for patients receiving oral antineoplastic agents: the e-oncohealth� app.

2018 ◽  
Author(s):  
Roberto Collado-Borrell ◽  
Vicente Escudero-Vilaplana ◽  
Almudena Ribed ◽  
Helena Anglada-Mart�nez ◽  
Maite Mart�n-Conde ◽  
...  
Keyword(s):  
Antineoplastic Agents ◽  
Smartphone App ◽  
Functional Requirements

Antineoplastic Agents. 489. Isolation and Structures of Meliastatins 1−5 and Related Euphane Triterpenes from the TreeMeliadubia1

2002 ◽  
Vol 65 (12) ◽  
pp. 1886-1891 ◽  
Author(s):  
George R. Pettit ◽  
Atsushi Numata ◽  
Chika Iwamoto ◽  
Hideaki Morito ◽  
Takeshi Yamada ◽  
...  
Keyword(s):  
Antineoplastic Agents

Icebreaker-inspired Janus nanomotors to combat barriers in the delivery of chemotherapeutic agents

Nanoscale ◽  
2021 ◽  
Author(s):  
Zhanlin Zhang ◽  
Dandan Zhang ◽  
Bo Qiu ◽  
Wenxiong Cao ◽  
Yuan Liu ◽  
...  
Keyword(s):  
Cellular Uptake ◽  
Cancer Chemotherapy ◽  
Antineoplastic Agents ◽  
Blood Circulation ◽  
Chemotherapeutic Agents ◽  
Tumor Infiltration ◽  
Intracellular Release ◽  
Pass Through

Cancer chemotherapy remains challenging to pass through various biological and pathological barriers from blood circulation, tumor infiltration and cellular uptake before intracellular release of antineoplastic agents. Herein, icebreaker-inspired Janus nanomotors...

Antineoplastic agents 100

Tetrahedron ◽  
1985 ◽  
Vol 41 (6) ◽  
pp. 985-994 ◽  
Author(s):  
G.R Pettit ◽  
Y Kamano ◽  
R Aoyagi ◽  
C.L Herald ◽  
D.L Doubek ◽  
...  
Keyword(s):  
Antineoplastic Agents

Antineoplastic agents and their oral manifestations

1977 ◽  
Vol 44 (4) ◽  
pp. 527-534 ◽  
Author(s):  
William K. Bottomley ◽  
Elliott Perlin ◽  
George R. Ross
Keyword(s):  
Antineoplastic Agents ◽  
Oral Manifestations

The Interferons

1984 ◽  
Vol 92 (3) ◽  
pp. 365-368 ◽  
Author(s):  
William J. Richtsmeier
Keyword(s):  
Nucleic Acid ◽  
Antineoplastic Agents ◽  
De Novo ◽  
Synthetic Activity ◽  
Antiviral Resistance ◽  
Virus Propagation ◽  
The Public ◽  
Interferon Inducers ◽  
Basic Criterion ◽  
Specific Receptors

The interferons (IFNs) are a group of proteins produced by cells of all vertebrate animals in response to a variety of stimuli. The ability to stimulate antiviral resistance, which was the first observed property of the IFNs, is still of great interest and remains the basic criterion by which the interferons are measured 1 (even into the most recent era of radioimmunoassay systems). It is the recent clinical uses of these substances as antineoplastic agents that has brought them to the attention of clinicians and the public in general. The IFN molecules exert their effects, much as hormones do, by attaching to specific receptors on other cells of the same species. Once attached, the IFNs induce cells to undergo a series of biochemical changes that renders them resistant to further virus propagation. To be an IFN, a substance must be a protein devoid of accompanying nucleic acid or endotoxin (both of which are interferon inducers). Treated cells must undergo de novo RNA and protein synthetic activity to acquire antiviral resistance.

ChemInform Abstract: ANTINEOPLASTIC AGENTS. 58. SYNTHESIS OF 3-ARYL-5-BROMO-2(5H)-FURANONES

1979 ◽  
Vol 10 (12) ◽  
Author(s):  
M. T. EDGAR ◽  
G. R. PETIT ◽  
T. H. SMITH
Keyword(s):  
Antineoplastic Agents

ChemInform Abstract: Antineoplastic Agents. Part 168. Isolation and Structure of Axinohydantoin

ChemInform ◽  
2010 ◽  
Vol 22 (8) ◽  
pp. no-no
Author(s):  
G. R. PETTIT ◽  
C. L. HERALD ◽  
J. E. LEET ◽  
R. GUPTA ◽  
D. E. SCHAUFELBERGER ◽  
...  
Keyword(s):  
Antineoplastic Agents

scholarly journals Antineoplastic Treatment of Advanced-Stage Non–Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011)

2017 ◽  
Vol 35 (5) ◽  
pp. 529-535 ◽  
Author(s):  
Cathy J. Bradley ◽  
K. Robin Yabroff ◽  
Angela B. Mariotto ◽  
Christopher Zeruto ◽  
Quyen Tran ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Antineoplastic Agents ◽  
Small Cell ◽  
Advanced Stage ◽  
Small Cell Lung ◽  
Medicare Data ◽  
Outcome Information ◽  
New Diagnosis

Purpose Multiple agents for advanced non–small-cell lung cancer (NSCLC) have been approved in the past decade, but little is known about their use and associated spending and survival. Methods We used SEER-Medicare data for elderly patients with a new diagnosis of advanced-stage NSCLC and were treated with antineoplastic agents between 2000 and 2011 (N = 22,163). We estimated the adjusted percentage of patients who received each agent, days while on treatment, survival, and spending in the 12 months after diagnosis. Results During the 12-year study period, a marked shift in treatment occurred along with a rapid adoption of pemetrexed (39.2%), erlotinib (20.3%), and bevacizumab (18.9%) and a decline in paclitaxel (38.7%), gemcitabine (17.0%), and vinorelbine (5.7%; all P < .05). The average total days on therapy increased by 5 days (from 103 to 108 days). Patients who received bevacizumab, erlotinib, or pemetrexed had the longest treatment durations on average (approximately 146 days v 75 days for those who did not receive these agents). Approximately 44% of patients received antineoplastic agents in the last 30 days of life throughout the study period. Acute inpatient spending declined (from $29,376 to $23,731), whereas outpatient spending increased 23% (from $37,931 to $46,642). Median survival gains of 1.5 months were observed. Conclusion Considerable shifts in the treatment of advanced-stage NSCLC occurred along with modest gains in survival and total Medicare spending. More precise outcome information is needed to inform value-based treatment decisions for advanced-stage NSCLC.

Sign in / Sign up

Export Citation Format

Share Document